CMS Should Retain Existing Part D Protected Classes, Senate Finance Committee Urges
This article was originally published in The Pink Sheet Daily
Executive Summary
A letter signed by the entire Senate committee questions CMS’ reasons for dropping antidepressants and antipsychotic drugs from protected status in the Medicare Part D program, arguing it could end up increasing costs to the program.
You may also be interested in...
Mental Health Drugs Face Contracting Challenges From Part D Formulary Proposal
CMS estimates that removing antidepressants, antipsychotics and immunosuppressants from “protected class” status in Medicare Part D could save $720 million between 2016 and 2019.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.
Biden vs Trump On Drug Pricing And Unfinished Business
While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs.